Peripherally acting µ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy

Joseph V. Pergolizzi, Robert B. Raffa, Marco Pappagallo, Charles Fleischer, Joseph Pergolizzi, Gianpietro Zampogna, Elizabeth Duval, Janan Hishmeh, Jo Ann LeQuang, Robert Taylor

Research output: Contribution to journalReview article

Abstract

Opioid-induced constipation (OIC), a prevalent and distressing side effect of opioid therapy, does not reliably respond to treatment with conventional laxatives. OIC can be a treatment-limiting adverse event. Recent advances in medications with peripherally acting µ-opioid receptor antagonists, such as methylnaltrexone, naloxegol, and alvimopan, hold promise for treating OIC and thus extending the benefits of opioid analgesia to more chronic pain patients. Peripherally acting µ-opioid receptor antagonists have been clinically tested to improve bowel symptoms without compromise to pain relief, although there are associated side effects, including abdominal pain. Other treatment options include fixed-dose combination products of oxycodone analgesic together with naloxone.

Original languageEnglish (US)
Pages (from-to)107-119
Number of pages13
JournalPatient Preference and Adherence
Volume11
DOIs
StatePublished - 2017

Fingerprint

Narcotic Antagonists
Constipation
Opioid Analgesics
pain
Pain
alvimopan
compromise
Oxycodone
medication
Therapeutics
Laxatives
Naloxone
event
Chronic Pain
Analgesia
Abdominal Pain
Analgesics

Keywords

  • Noncancer pain patients
  • Opioid bowel disorder
  • Opioid-associated side effects
  • Opioid-induced constipation
  • PAMORA
  • Peripherally acting mu-opioid receptor antagonist

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Social Sciences (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy

Cite this

Peripherally acting µ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy. / Pergolizzi, Joseph V.; Raffa, Robert B.; Pappagallo, Marco; Fleischer, Charles; Pergolizzi, Joseph; Zampogna, Gianpietro; Duval, Elizabeth; Hishmeh, Janan; LeQuang, Jo Ann; Taylor, Robert.

In: Patient Preference and Adherence, Vol. 11, 2017, p. 107-119.

Research output: Contribution to journalReview article

Pergolizzi, JV, Raffa, RB, Pappagallo, M, Fleischer, C, Pergolizzi, J, Zampogna, G, Duval, E, Hishmeh, J, LeQuang, JA & Taylor, R 2017, 'Peripherally acting µ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy' Patient Preference and Adherence, vol. 11, pp. 107-119. https://doi.org/10.2147/PPA.S78042
Pergolizzi, Joseph V. ; Raffa, Robert B. ; Pappagallo, Marco ; Fleischer, Charles ; Pergolizzi, Joseph ; Zampogna, Gianpietro ; Duval, Elizabeth ; Hishmeh, Janan ; LeQuang, Jo Ann ; Taylor, Robert. / Peripherally acting µ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy. In: Patient Preference and Adherence. 2017 ; Vol. 11. pp. 107-119.
@article{393d0045e18d4f0d8e41a179c629d8bf,
title = "Peripherally acting µ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy",
abstract = "Opioid-induced constipation (OIC), a prevalent and distressing side effect of opioid therapy, does not reliably respond to treatment with conventional laxatives. OIC can be a treatment-limiting adverse event. Recent advances in medications with peripherally acting µ-opioid receptor antagonists, such as methylnaltrexone, naloxegol, and alvimopan, hold promise for treating OIC and thus extending the benefits of opioid analgesia to more chronic pain patients. Peripherally acting µ-opioid receptor antagonists have been clinically tested to improve bowel symptoms without compromise to pain relief, although there are associated side effects, including abdominal pain. Other treatment options include fixed-dose combination products of oxycodone analgesic together with naloxone.",
keywords = "Noncancer pain patients, Opioid bowel disorder, Opioid-associated side effects, Opioid-induced constipation, PAMORA, Peripherally acting mu-opioid receptor antagonist",
author = "Pergolizzi, {Joseph V.} and Raffa, {Robert B.} and Marco Pappagallo and Charles Fleischer and Joseph Pergolizzi and Gianpietro Zampogna and Elizabeth Duval and Janan Hishmeh and LeQuang, {Jo Ann} and Robert Taylor",
year = "2017",
doi = "10.2147/PPA.S78042",
language = "English (US)",
volume = "11",
pages = "107--119",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Peripherally acting µ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy

AU - Pergolizzi, Joseph V.

AU - Raffa, Robert B.

AU - Pappagallo, Marco

AU - Fleischer, Charles

AU - Pergolizzi, Joseph

AU - Zampogna, Gianpietro

AU - Duval, Elizabeth

AU - Hishmeh, Janan

AU - LeQuang, Jo Ann

AU - Taylor, Robert

PY - 2017

Y1 - 2017

N2 - Opioid-induced constipation (OIC), a prevalent and distressing side effect of opioid therapy, does not reliably respond to treatment with conventional laxatives. OIC can be a treatment-limiting adverse event. Recent advances in medications with peripherally acting µ-opioid receptor antagonists, such as methylnaltrexone, naloxegol, and alvimopan, hold promise for treating OIC and thus extending the benefits of opioid analgesia to more chronic pain patients. Peripherally acting µ-opioid receptor antagonists have been clinically tested to improve bowel symptoms without compromise to pain relief, although there are associated side effects, including abdominal pain. Other treatment options include fixed-dose combination products of oxycodone analgesic together with naloxone.

AB - Opioid-induced constipation (OIC), a prevalent and distressing side effect of opioid therapy, does not reliably respond to treatment with conventional laxatives. OIC can be a treatment-limiting adverse event. Recent advances in medications with peripherally acting µ-opioid receptor antagonists, such as methylnaltrexone, naloxegol, and alvimopan, hold promise for treating OIC and thus extending the benefits of opioid analgesia to more chronic pain patients. Peripherally acting µ-opioid receptor antagonists have been clinically tested to improve bowel symptoms without compromise to pain relief, although there are associated side effects, including abdominal pain. Other treatment options include fixed-dose combination products of oxycodone analgesic together with naloxone.

KW - Noncancer pain patients

KW - Opioid bowel disorder

KW - Opioid-associated side effects

KW - Opioid-induced constipation

KW - PAMORA

KW - Peripherally acting mu-opioid receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=85011653973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011653973&partnerID=8YFLogxK

U2 - 10.2147/PPA.S78042

DO - 10.2147/PPA.S78042

M3 - Review article

VL - 11

SP - 107

EP - 119

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

SN - 1177-889X

ER -